U.S. pre-market trading saw broad declines in the storage and optical communication sectors, with Micron and SanDisk falling around 3%.

According to market data from BIT (bit.com), biotech stocks are seeing hype in the US stock market. US biotech firm Moderna (MRNA) closed up 14.36% with a trading volume of $7.636 billion, while Merck (MRK) closed up 3.84%. Moderna and Merck recently jointly announced that their first personalized mRNA cancer therapy, intismeran autogene, has succeeded in global Phase III clinical trials for high-risk melanoma, marking a milestone breakthrough in the field of tumor immunotherapy. Multiple major banks have raised Moderna's price targets: Bank of America lifted its target from $40 to $170 and upgraded its rating to "Neutral"; Piper Sandler raised its target from $77 to $167, maintaining an "Overweight" rating; Goldman Sachs raised its target from $67 to $120, keeping a "Neutral" rating; JPMorgan raised its target from $40 to $77; Barclays raised its target from $48 to $125. According to Bitget market data, Hong Kong-listed stocks opened higher today: CanSino Biologics surged 17%, Innovent Biologics rose over 10%, Hutchison China MediTech gained over 7%, Kangfang Biologics climbed over 6%, and Rongchang Biologics advanced over 4%. CanSino Biologics announced that its subsidiary CanSino Shanghai has officially signed a strategic cooperation framework agreement on joint development of personalized mRNA therapeutic cancer vaccines with Deppon Biologics, to jointly promote the R&D and commercialization of such vaccines.

On-chain analyst Ai Yi (@ai_9684xtpa) detected that new address 0xAef…Dc00B accumulated 20,000 ETH over the past 50 minutes, valued at $48.89 million, and is likely linked to BitMine. BitMine currently holds a total of 5,847,611 ETH, worth roughly $14.4 billion (excluding this suspected activity), with an average cost of approximately $3,359, resulting in an unrealized loss of $5.27 billion.

Robotics foundation model startup Generalist has closed an approximately $200 million extension funding round led by 8VC, bringing its post-money valuation to $3 billion. This is an extension of the $400 million Series B round the company announced in June, which was led by Radical Ventures and valued Generalist at $2 billion at the time. Total funding raised by the startup now stands at $600 million following this latest extension. Founded in 2024, Generalist’s founding team includes former Google DeepMind researchers Pete Florence and Andy Zeng, plus former Boston Dynamics engineer Andrew Barry. Early backers of the firm include NVIDIA, Union Square Ventures, Bezos Expeditions, and AI researcher Li Feifei. The company’s newly launched Gen 1.5 model claims to enable robots to master new tasks from just 3 to 12 seconds of video demonstrations. It is currently collaborating with a small number of clients to customize models for specific scenarios based on feedback.

According to EmberCN’s monitoring, Polychain redeemed a total of 131.8 million EIGEN tokens at the end of May. Of these, 46.86 million were re-staked one month prior, while another 14.65 million were transferred to Coinbase Prime today, valued at approximately $3.09 million.

TRON reached 400M total users in just 8.16 years, much faster than Bitcoin and Ethereum. Bitcoin took 9.4 years to reach 400M users, while Ethereum took over 10 years.

Nvidia will release its fiscal 2027 second-quarter financial results after U.S. stock market close on Wednesday (early Thursday Beijing time) and hold an earnings call at 5 p.m. Eastern Time (5 a.m. Thursday Beijing time). The chipmaker has for multiple consecutive quarters delivered both results and guidance that beat expectations. As of its fiscal 2027 first quarter (reported on May 20, 2026), Nvidia has posted 13 straight quarters of revenue and adjusted earnings per share (EPS) exceeding analyst consensus estimates, plus 13 consecutive quarters of actual revenue topping the midpoint of its own prior-quarter revenue guidance. Markets are closely watching whether this streak will continue. Wall Street analysts’ consensus forecasts call for revenue of around $92.18 billion, up roughly 97% year-over-year, and adjusted non-GAAP EPS of about $2.09, a 99% year-over-year increase. Nvidia’s prior guidance had projected revenue of roughly $91 billion, representing a 95% year-over-year rise. Key focus areas for the upcoming results include the performance of its data center business—specifically shipments and demand for Blackwell architecture products, gross margin, next-quarter guidance, and an update on sales to the Chinese market.